泛BCL-2抑制剂AT-101靶向癌症干细胞治疗胃食管癌的临床前与临床研究
本研究通过体外和体内临床前实验探讨BCL-2抑制剂AT-101靶向胃食管癌癌症干细胞及抗凋亡蛋白的作用机制,并在13例食管癌患者中开展AT-101联合放化疗的初步临床试验。结果显示AT-101可诱导凋亡、抑制增殖并下调YAP-1/SOX9等干细胞调控基因,与多西他赛联用增强抗肿瘤活性;临床试验观察到显著的临床完全缓解和令人鼓舞的总生存。
要点
- AT-101可下调胃食管癌细胞中YAP-1/SOX9等癌症干细胞调控基因。
- AT-101联合多西他赛在体内外均增强抗肿瘤活性并降低干细胞标志物。
- 13例食管癌患者接受AT-101联合放化疗后观察到显著临床完全缓解。
核心结论
- 临床前和临床数据提示AT-101通过靶向癌症干细胞通路克服胃食管癌治疗抵抗。
研究设计与样本
- 开展体外和体内临床前研究以确立AT-101靶向癌症干细胞和抗凋亡蛋白的作用机制。
- 完成一项在胃食管癌患者中将AT-101加入标准放化疗的初步临床试验。
- 初步临床试验中13例食管癌患者口服AT-101同步接受放化疗。
主要发现
- 胃癌组织中观察到BCL-2和MCL-1过表达。
- AT-101在MCL-1/BCL-2高表达胃癌细胞中诱导凋亡、减少增殖和肿瘤球形成。
- AT-101显著下调胃食管癌细胞系中控制癌症干细胞的YAP-1/Sox9基因,与BCL-2/MCL-1表达无关。
- 多西他赛加入AT-101可放大其抗增殖和诱导凋亡效应。
- 体内研究证实AT-101联合多西他赛显示更强抗肿瘤活性并显著降低癌症干细胞标志物YAP1/SOX9。
临床怎么用
- AT-101联合标准放化疗在食管癌患者中显示出临床完全缓解和生存获益的初步信号。
- AT-101与多西他赛联用可能增强抗肿瘤活性并靶向癌症干细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gastro-oesophageal cancers (GEC) are resistant to therapy and lead to poor prognosis. The cancer stem cells (CSCs) and antiapoptotic pathways often confer therapy resistance. We sought to elucidate the antitumour action of a BCL-2 inhibitor, AT101 in GEC in vitro, in vivo and in a clinical trial. METHODS: Extensive preclinical studies in vitro and in vivo were carried out to establish the mechanism action of AT101 on targeting CSCs and antiapoptotic proteins. A pilot clinical trial in patients with GEC was completed with AT-101 added to standard chemoradiation. RESULTS: Overexpression of BCL-2 and MCL-1 was noted in gastric cancer tissues (GC). AT-101 induced apoptosis, reduced proliferation and tumour sphere formation in MCL-1/BCL-2 high GC cells. Interestingly, AT101 dramatically downregulated genes (YAP-1/Sox9) that control CSCs in GEC cell lines regardless of BCL-2/MCL-1 expression. Addition of docetaxel to AT-101 amplified its antiproliferation and induced apoptosis effects. In vivo studies confirmed the combination of AT101 and docetaxel demonstrated stronger antitumour activity accompanied with significant decrease of CSCs biomarkers (YAP1/SOX9). In a pilot clinical trial, 13 patients with oesophageal cancer (EC) received AT101 orally concurrently with chemoradiation. We observed dramatic clinical complete responses and encouraging overall survival in these patients. Clinical specimen analyses revealed that AT-101 dramatically reduced the expression of CSCs genes in treated EC specimens indicating antitumour activity of AT101 relies more on its anti-CSCs activity. CONCLUSIONS: Our preclinical and clinical data suggest that AT-101 overcomes resistance by targeting CSCs pathways suggesting a novel mechanism of action of AT101 in patients with GEC.
引用
- Song S, Chen Q, Li Y, et al. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021. PMID: 33487592. doi:10.1136/gutjnl-2020-321175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。